Авторы

  • Sultonova D.

Ключевые слова:

axial spondylitis; axial spondyloarthritis; IL-17; IL-23; MAIT cells; STAT3; biomarkers; MRI; precision medicine.

Библиографические ссылки

1. Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis—insights into pathogenesis. Nat Rev Rheumatol. 2016;12(2):81–91. doi:10.1038/nrrheum.2015.133

2. Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739–1747.doi:10.1136/annrheumdis-2014-206323

3. Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7):730–738.doi:10.1038/ng.2667

4. Cuthbert RJ, Fragkakis EM, Dunsmuir R, et al. Group 3 innate lymphoid cells in human enthesis. Ann Rheum Dis. 2017;76(2):423–431.doi:10.1136/annrheumdis-2016-209254

5. Gracey E, Qaiyum Z, Almaghlouth I, et al. IL-17 in the pathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2020;16(8):453–466.doi:10.1038/s41584-020-0447-2

6. Hayashi E, Chiba A, Tada K, et al. Involvement of mucosal-associated invariant T cells in ankylosing spondylitis. Ann Rheum Dis. 2016;75(8):1466–1473. doi:10.1136/annrheumdis-2015-207324

7. Kiltz U, Baraliakos X, Braun J. Predictors of response to biological therapies in axial spondyloarthritis. Rheumatology (Oxford). 2019;58(Suppl 6):vi30–vi42. doi:10.1093/rheumatology/ kez337

8. Maksymowych WP, Lambert RGW. Imaging the sacroiliac joint and spine in spondyloarthritis. Nat Rev Rheumatol. 2017; 13(8):462–474. doi:10.1038/nrrheum.2017.97

9. Maksymowych WP, Pedersen SJ, Weber U, et al. Imaging in axial spondyloarthritis: current state and future directions. Rheum Dis Clin North Am. 2020; 46(2):237–252. doi:10.1016/j.rdc.2020.01.003

10. Maksymowych WP, Wichuk S, Dougados M, et al. MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation. Ann Rheum Dis. 2019; 78(11):1550–1558. doi:10.1136/annrheumdis-2019-215589

11. McGonagle D, Watad A, Sharif K, Bridgewood C. The early phase of spondyloarthritis. Nat Rev Rheumatol. 2019; 15(9):559–570.doi:10.1038/s41584-019-0277-6

12. Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Biomarkers and precision medicine in axial spondyloarthritis. Nat Rev Rheumatol. 2021; 17(7):431–444. doi:10.1038/s41584-021-00628-0

13. Poddubnyy D, Sieper J. Diagnostic delay in axial spondyloarthritis: a systematic review. Curr Opin Rheumatol. 2017;29(4):363–369.doi:10.1097/BOR.0000000000000393

14. Reveille JD. Genetics of spondyloarthritis-beyond HLA-B27. Nat Rev Rheumatol. 2012;8(5):296–304. doi:10.1038/nrrheum.2012.41

15. Robinson PC, Brown MA. The microbiome in ankylosing spondylitis and related spondyloarthritides. Curr Opin Rheumatol. 2014; 26(4):393–399. doi:10.1097/BOR.0000000000 000069

16. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783. doi:10.1136/ard.2009.108233

17. Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation and tissue damage in spondyloarthritis. Nat Rev Rheumatol. 2013; 9(12):719–730. doi:10.1038/ nrrheum.2013.173

18. Schett G, Lories RJ. Detrimental and protective roles of inflammation in bone. Nat Rev Rheumatol. 2017;13(11):663–673. doi:10.1038/nrrheum.2017.158

19. Schett G, McGonagle D, Tanaka Y, et al. Pathogenesis of spondyloarthritis: immune–bone interactions. Nat Rev Rheumatol. 2022;18(9):507–521. doi:10.1038/s41584-022-00797-3

20. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt⁺ CD3⁺CD4⁻CD8⁻ entheseal resident T cells. Nat Med. 2012; 18(7):1069–1076. doi:10.1038/nm.2817

21. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84. doi:10.1016/S0140-6736(16)31591-4

22. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563–2574.doi:10.1056/NEJMra1406182

23. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS–EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991. doi:10.1136/annrheumdis-2016-210770

24. van der Heijde D, Ramiro S, Landewé R, et al. 2022 update of the ASAS–EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023;82(1):19–34.doi:10.1136/ard-2022-223296

25. Zhao SS, Pittam B, Harrison NL, Ahmed AE, Goodson NJ, Hughes DM. Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(4):1620–1628.doi:10.1093/rheumatology/keaa621